AstraZeneca to invest $50 billion in the U.S. as pharma tariffs weigh
The Anglo-Swedish biotech company, which is headquartered in Cambridge, England, said the "cornerstone" of the commitment would be a new multi-billion dollar facility to produce its weight management and metabolic portfolio, including its oral GLP-1 obesity pill.
The facility, planned for the Commonwealth of Virginia, is set to be AstraZeneca's largest single manufacturing investment in the world and will "leverage AI, automation and data analytics to optimize production," the company said.
The latest funding will also expand research and development and cell therapy manufacturing in Maryland, Massachusetts, California, Indiana and Texas, and create "tens of thousands of jobs," AstraZeneca added.
CEO Pascal Soriot said the commitment underpins the firm's "belief in America's innovation in biopharmaceuticals" and would support its ambition to reach $80 billion in annual revenue by 2030, half of which is expected to come from the U.S.
AstraZeneca, which made international headlines by developing one of the key Covid-19 vaccines, has long been prioritizing the U.S. market. The United States accounted for over 40% of the company's annual revenues in 2024.
In November, shortly after the U.S. presidential election, AstraZeneca announced a $3.5 billion U.S. investment. Earlier this month, The Times reported that the firm may move its listing from London to the U.S., in what analysts said would be a major blow to the U.K.'s public markets.
AstraZeneca is the most valuable business listed on London's FTSE 100. The company declined to comment on the Times report.
AstraZeneca's funding announcement follows similar moves by global pharmaceutical firms — including Novartis, Sanofi and Roche and U.S.-headquartered Eli Lilly and Johnson & Johnson — who have all vowed over recent months to ramp up their U.S. investment amid U.S. President Donald Trump's demands to reshore domestic manufacturing.
The industry is awaiting further clarity on the Trump administration's pharma tariffs, with the final outcome of a Section 232 investigation into the sector due at the end of this month. An effort to rebalance U.S. drug prices with those paid by other countries is also underway.
Trump earlier this month suggested that the industry could face levies of up to 200%, with a brief 12-18 month grace period to allow firms to relocate manufacturing stateside. However, many firms and analysts have dubbed the time frame as insufficient.
"Typically for most medicines it's a three to four year horizon. We're working very hard to accelerate that as fast as we can and demonstrate we're making the investments we have planned," Novartis CEO Vas Narasimhan said last week during an earnings call, adding that he hoped the administration would make allowances.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
13 minutes ago
- The Hill
EPA delays methane emission rule for oil and gas
The Environmental Protection Agency (EPA) is delaying the implementation of restrictions on planet-warming methane emissions from oil and gas drilling as it considers unwinding the requirements entirely. The Biden administration issued a rule that requires oil and gas drillers to take steps to limit leaks and, at new wells, to phase out the routine burning of excess gas, also known as flaring. The rule would have been expected to cut down on methane emissions and also to reduce releases of toxic air pollutants. This week, the Trump administration quietly issued an interim final rule that pushes back the policy's compliance deadlines. It said it was doing so 'to address legitimate concerns…that certain regulatory provisions are not currently workable or contain problematic regulatory language that frustrates compliance.' Under the interim final rule, companies will have 18 months before they need to install certain pollution controls. Critics called it a corporate giveaway. 'Many oil and gas operators have already been complying with these requirements for nearly a year, while others are investing and planning ways to reduce methane pollution to meet the standards. Delaying implementation will simply give a handout to the worst actors who would be able to continue their polluting ways with zero consequences or accountability to neighboring communities,' said Mahyar Sorour, director of the Sierra Club's Beyond Fossil Fuels Policy in a written statement. The Trump administration has also put the regulation in question on a hit list of Biden-era rules that it may reverse. The latest move comes in the same week that the agency proposed to overturn its landmark finding that greenhouse gases such as methane pose a threat to public health through the changing climate.
Axios
13 minutes ago
- Axios
Trump ends de minimis tariff exemption, sets copper and Brazil levies
President Trump on Wednesday took another sweeping series of tariff actions, formally imposing new levies on copper and revoking a global exemption on tariffs for packages worth less than $800. Why it matters: Ending the so-called de minimis exemption will make low-price goods from around the world more expensive for American consumers. The suspension was already in place for China and had a serious impact on major Chinese retailers like Shein and Temu. The copper levy will increase prices substantially on one of the most vital metals to the American economy. The big picture: After months of on-off trade policy, Trump is barreling firmly ahead with this Friday's deadline to broadly raise, or impose, tariffs on key goods and major allies.
Boston Globe
13 minutes ago
- Boston Globe
US stock market holds steady after the Fed makes no move on interest rates
Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up 'Cutting through the noise of the swings in imports, the economy is still chugging along, but it is showing signs of sputtering,' said Brian Jacobsen, chief economist at Annex Wealth Management. Advertisement The data reinforced the dilemma facing Fed officials as they voted Wednesday on what to do with interest rates. They could have lowered rates, which would give a boost to the economy as Trump has so been angrily calling for. But lower rates could also give inflation more fuel when Trump's tariffs may be set to increase prices for U.S. households. Trump on Wednesday announced a 25% tariff on imports coming from India, along with an additional tax because of India's purchases of Russian oil, beginning on Aug. 1. That's when stiff tariffs Trump has proposed for many other countries are also scheduled to kick in, unless they reach trade deals that lower the rates. Advertisement Fed Chair Jerome Powell has been insisting that he wants to see more data about how tariffs are affecting inflation and the economy before the central bank makes its next move, and he will speak shortly to offer more details about the decision. Two officials on the Fed's committee did dissent in Wednesday's vote, an indication that Powell may face increasing pressure to cut rates soon. Much of Wall Street expects the Fed to resume lowering rates in September. It's been on hold this year after cutting rates several times late last year. The yield on the two-year U.S. Treasury note edged up to 3.87% from 3.86% late Tuesday. It tends to closely follow expectations for what the Fed will do with its overnight interest rate. The 10-year Treasury, which also takes into account longer-term expectations for the economy and inflation, was holding at 4.34%. On Wall Street, stocks were mixed as most big U.S. companies continue to report profits for the spring that were bigger than analysts expected. Humana rose 10.3% after the insurer and health care giant reported stronger results for the spring than expected. It also raised its forecasts for profit and revenue over the full year. Video-game maker Electronic Arts climbed 7% after likewise topping Wall Street's expectations. The company said it saw better-than-expected contributions from EA Sports and other games, and it will reveal its new Battlefield game on Thursday. Companies are under pressure to deliver solid profit growth. They need to in order to justify the big jumps in their stock prices during recent months, which has caused some critics to say the broad U.S. stock market looks too expensive. Advertisement Trane Technologies, whose stock came into the day with a 27.5% gain for the year so far, tumbled even though it reported a stronger-than-expected profit for the latest quarter. The heating, ventilation and air conditioning company's revenue came up short of analysts' estimates, as did its forecast for profit in the current quarter. It dropped 8%. Starbucks swung between gains and losses after it reported a weaker profit than analysts expected as it tries to turn around its operations. The company is hoping to boost its performance through improved store operations and new products, including a cold foam protein drink. Its stock was most recently up 0.4%. Palo Alto Networks fell 4.4% after saying it would buy CyberArk, an identity-security company, for $25 billion in cash and stock. CyberArk shares added 1.4%. In stock markets abroad, indexes were mixed across Europe and Asia. Hong Kong's Hang Seng fell 1.4%, and South Korea's Kospi rose 0.7% for two of the bigger moves. AP Business Writers Matt Ott and Elaine Kurtenbach contributed.
